Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science
The company's lead drug candidate, omecamtiv mecarbil, directly activates cardiac myosin, increasing cardiac function without changing contraction rates. This novel mechanism may provide a new therapeutic strategy for improving cardiac performance in patients with systolic heart failure.